Virus Or Bacteriophage, Except For Viral Vector Or Bacteriophage Vector; Composition Thereof; Preparation Or Purification Thereof; Production Of Viral Subunits; Media For Propagating Patents (Class 435/235.1)
  • Patent number: 11400150
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: August 2, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Patent number: 11378565
    Abstract: A method for in-ova fertilisation determination and gender determination on a closed egg. The aim is to specify a method for the in-ovo fertilisation determination and gender determination on a closed egg. This aim is achieved by a method in which a closed egg is positioned, candled and/or illuminated, next an image of the closed egg is recorded, then the captured data are evaluated and the position of the cardiovascular system located in the egg is calculated. A detection unit is adjusted via the calculated position of the cardiovascular system by means of a positioning unit and subsequently the blood is stimulated, then the blood-specific and blood-foreign absorption spectra are detected and selected, the fertilisation is ascertained and then the spectra containing blood-foreign information are compensated by a compensation method and the spectra are classified for sex determination.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: July 5, 2022
    Assignee: Technische Universität Dresden
    Inventors: Grit Preusse, Gerald Steiner, Roberta Galli, Edmund Koch, Christian Schnabel
  • Patent number: 11352439
    Abstract: Modified macrophage immune cells are provided for treatment of cancer and other diseases.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: June 7, 2022
    Inventors: Kim Leslie O'Neill, Scott Weber
  • Patent number: 11351243
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: June 7, 2022
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, David Ewell Slade, Siao-Kun W. Welch
  • Patent number: 11340238
    Abstract: The present invention provides an in vitro method for detecting the presence of neutralizing antibodies against recombinant human insulin (rHI) in human serum. It also provides a kit for an in vitro method of detection of the presence of recombinant human insulin (rHI) neutralizing antibodies.
    Type: Grant
    Filed: October 15, 2016
    Date of Patent: May 24, 2022
    Assignee: BIOCON LIMITED
    Inventors: Abhishek Kulshrestha, Ravi Shankar Maurya, Sudeep Sabde, Pallavi Hajela, Pawan Kalani, Ramakrishnan Melarkode, Narendra Chirmule
  • Patent number: 11306291
    Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: April 19, 2022
    Assignee: UNIQURE IP B.V.
    Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria Christiaan Hermens
  • Patent number: 11299752
    Abstract: The present disclosure provides a method of generating a stable producer cell line. The generation of stable producer cell lines, such as those provided in accordance with the present invention, increases the reproducibility and ease of creating high titer lentiviral stocks while easing biosafety concerns and the variation in expressed envelope proteins defines the tropism of the generated virus. The present disclosure also provides for a novel lentiviral transfer vector plasmid.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: April 12, 2022
    Assignee: CSL Behring Gene Therapy, Inc.
    Inventors: Chi-Lin Lee, Jeffrey S Bartlett
  • Patent number: 11299715
    Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 12, 2022
    Assignee: Genzyme Corporation
    Inventors: Peter Pechan, Jeffery Ardinger, Abraham Scaria, Samuel Wadsworth
  • Patent number: 11286500
    Abstract: A nucleic acid molecule can code for an Orf virus vector promoter. A recombinant Orf virus vector can be included in a cell. The nucleic acid molecule, the vector and/or the cell can be included in a composition. The recombinant Orf virus vector can be used for the production of a foreign gene.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: March 29, 2022
    Assignee: EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT
    Inventors: Hanns-Joachim Rziha, Ralf Amann
  • Patent number: 11273127
    Abstract: Embodiments of the present invention provide for novel compositions and methods for making and using a thermally stable human papilloma virus (HPV) formulation or other stabilized multimeric virus formulation. Certain embodiments concern lyophilizing HPV formulations in the presence or absence of adjuvants. Other embodiments concern lypophilizing HPV capsomere vaccines in order to increase stability of an immunogenic composition against HPV infection for storage, delivery and use. In yet other embodiments, a single immunogenic composition can include a thermally stable formulation of multiple virus serotypes. Yet other embodiments disclosed herein concern multi-targeted antigen complexes lyophilized in formulations of use to prolong stability and/or enhance immunogenicity. Other embodiments concern exposing lyophilized multi-targeted antigen complexes to elevated temperatures to enhance immunogenicity of the antigens of the complex to multiple pathogens.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: March 15, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Theodore Randolph, Robert Garcea
  • Patent number: 11268116
    Abstract: Disclosed are methods and kits for endonuclease-assisted DNA amplification reaction using decontaminated primer solutions that are pre-treated with a nuclease. Nucleic acid amplification assays that employ nuclease-resistant, inosine-containing primers, endonuclease V enzymes to introduce a nick into a target DNA comprising at least one inosine, and a DNA polymerase to generate amplicons of a target DNA are also disclosed.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 8, 2022
    Assignee: GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
    Inventors: Robert Scott Duthie, John Richard Nelson, Anuradha Sekher
  • Patent number: 11261416
    Abstract: We have modified a commercially-available adherent cell culture bioreactor in several ways to increase productivity of cultured cells, while decreasing contamination risk. We found that modifying a commercially-available adherent cell culture bioreactor to provide for slower cell culture medium flow unexpectedly and dramatically increases the productivity of the cultured adherent cells. We also developed a new sampling manifold configuration and new way of taking samples, to reduce contamination risk.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: March 1, 2022
    Assignee: Trizell Ltd.
    Inventors: Piia Kristiina Valonen, Hanna P. Lesch, Eva Kristiina Rasanen, Tarja Hannele Tuunanen, Minna Kristiina Karhinen, Seppo Yla-Herttuala
  • Patent number: 11254964
    Abstract: The present invention relates to a method of maintaining cell viability at a level of at least 80% for up to 14 days in a fed-batch culture of cells producing a recombinant protein, the method comprising maintaining the cell culture medium at a pH of 6.5 to 7.0 and at a temperature of 31° C. to 35° C. for at least 5 consecutive days of the duration of the cell culture method.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: February 22, 2022
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Matthieu Stettler, Hervé Broly, Thomas Solacroup, Yolande Rouiller
  • Patent number: 11242504
    Abstract: We have modified a commercially-available adherent cell culture bioreactor, developing a new sampling manifold configuration and new way of taking samples to reduce contamination risk.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: February 8, 2022
    Assignee: Trizell Ltd.
    Inventors: Piia Kristiina Valonen, Eva Kristiina Rasanen, Tarja Hannele Tuunanen, Milla Jonna Karoliina Karnaattu, Achim Muller, Minna Kristiina Karhinen, Seppo Yla-Herttuala
  • Patent number: 11219901
    Abstract: The invention concerns a robotic method for coating the bottom surface of at least one well of a multiwell plate by a polyelectrolyte multilayer film, the multiwell plate obtainable according to the method and the use thereof for cell culture.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: January 11, 2022
    Assignees: INSTITUT POLYTECHNIQUE DE GRENOBLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Catherine Cécile Picart, Jie Liu, Fabien Dalonneau, Paul Machillot
  • Patent number: 11208630
    Abstract: Provided herein are methods of improving rAAV production in cells, the method comprising increasing the salt concentration in the media in which the cells are infected or transfected, cultured, or in which they produce AAV. Aspects of the disclosure relate to improved methods of rAAV production by co-infecting suspension adapted cells (e.g., suspension adapted HEK293 cells) with viruses that encode one or more AAV components for producing rAAV particles within the suspension adapted cells.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: December 28, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Nathalie Clement, Barry John Byrne, Laura A. Small
  • Patent number: 11191733
    Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at ?5 to 50° C. to introduce the drug into the empty capsid or the empty particle.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: December 7, 2021
    Assignee: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Takashi Okada, Shin'ichi Takeda, Hiromi Kinoh
  • Patent number: 11193931
    Abstract: A VAMP epitope suitable for generating an antibody against a VAMP C-terminal neurotoxin cleavage product. Method of using such an epitope to generate an antibody against cleaved VAMP. Method of using such an antibody to assay for cleavage of a VAMP by clostridial neurotoxin.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: December 7, 2021
    Assignee: IPSEN BIOPHARM LIMITED
    Inventors: Bryony Gray, Verity Cadd, Matthew Beard
  • Patent number: 11193111
    Abstract: Virus particle multimers and methods of making and using such virus particle multimer are described. Virus particle multimers are constructed by preparing a plurality of asymmetrically functionalized virus particles bearing one or more functional groups and contacting the asymmetrically functionalized virus particles with a first linker molecule that reacts with the functional groups to form a virus particle multimer that includes a plurality of asymmetrically functionalized virus particles connected by the linker molecule. The asymmetrically functionalized virus particles are typically prepared by attaching the virus particles to a support surface to allow asymmetrical functionalization to be introduced.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: December 7, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole F. Steinmetz, Amy M. Wen
  • Patent number: 11191826
    Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: December 7, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Miguel A. Munoz Alia, Stephen James Russell
  • Patent number: 11124546
    Abstract: This invention relates to modified parvovirus capsid proteins with enhanced transduction efficiency, viral vectors comprising the same, and methods of using the same for delivery of nucleic acids to a cell or a subject.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 21, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Richard Jude Samulski, Jayme Warischalk
  • Patent number: 11119103
    Abstract: Provided herein is a test system comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen, SARS-CoV-2 S2 antigen, and binding moieties that specifically bind to human IgG, human IgA, and human IgM. Also provided are methods of detecting SARS-CoV-2 antibodies in a sample using the test system.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: September 14, 2021
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona, a body corporate
    Inventors: Deepta Bhattacharya, Ryan Sprissler, Janko Nikolich-Zugich, Matthew Kaplan, Tyler Ripperger, Jennifer Uhrlaub, Makiko Watanabe, Rachel Wong
  • Patent number: 11110138
    Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 7, 2021
    Assignee: CELVERUM INC.
    Inventors: David Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
  • Patent number: 11103570
    Abstract: The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against FMDV infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a FMDV protein. The invention also relates to products, methods and uses thereof, e.g., suitable to induce a protective immune response in a subject.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: August 31, 2021
    Assignee: Bavarian Nordic A/S
    Inventors: Robin Steigerwald, Markus Kalla
  • Patent number: 11034946
    Abstract: A engineered alpha-galactosidase A polypeptide comprising SEQ ID NO: 1 having at least one non-glycosylation mutation; and at least one glycosylation compensatory mutation is claimed.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: June 15, 2021
    Assignee: Research Foundation of The City University of New York
    Inventors: David H. Calhoun, Erin S. Stokes, M. Lane Gilchrist
  • Patent number: 11034931
    Abstract: The invention relates to yeast cells with useful characteristics, including being capable of utilizing panose as sole carbon source and/or capable of utilizing one or more dipeptidesas sole nitrogen source. The invention also relates to yeast cells with useful genotypes including comprising at least 4 allelic genes encoding IMA1p and/or at least two allelic genes encoding IMA5p.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: June 15, 2021
    Assignee: Carlsberg Breweries A/S
    Inventors: Natalia Y. Solodovnikova, Jeppe Frank Andersen, Rosa Garcia Sanchez, Zoran Gojkovic
  • Patent number: 11000560
    Abstract: The present invention relates to oncolytic adenoviruses with functional deletions of immunodominant T-cell epitopes of adenovirus proteins, as well as to methods of using the oncolytic adenoviruses for the treatment of diseases, such as cancer. The oncolytic adenoviruses may also contain one or more heterologous nucleic acid sequences each encoding a tumor antigen or epitope. The oncolytic adenoviruses may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: May 11, 2021
    Assignee: VCN BIOSCIENCES, S.L.
    Inventors: Ramon Alemany, Raul Gil, Miriam Bazan
  • Patent number: 10994028
    Abstract: Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: May 4, 2021
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Guang Qu, John Fraser Wright
  • Patent number: 10975138
    Abstract: Production of etanercept using perfusion methods achieves attractive yields of properly folded protein. Desired temperature, feed media, titers and percent correctly folded protein are disclosed.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: April 13, 2021
    Assignee: Coherus BioSciences, Inc.
    Inventors: Ela Puchacz, James Russell Grove
  • Patent number: 10975425
    Abstract: A novel assay and a suite of devices may isolate nucleic acids from prokaryotic and eukaryotic cells and prepare samples for real-time (quantitative) polymerase chain reaction (PCR) analysis. The assay may employ an aqueous-based non-alcohol approach that yields robust RNA quality. The suite of ready-to-use devices may provide pre-loaded reagents in liquid and lyophilized formats to enable rapid manual operation in a laboratory or remote field environments. The assay and devices may be particularly suitable to analysis in microgravity or deep space environments.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: April 13, 2021
    Assignee: United States of America as Represented by the Administrator of NASA
    Inventors: Travis David Boone, Jimmy Kar Chuen Jung, Macarena Parra, Mark Brown
  • Patent number: 10928383
    Abstract: A method for predicting an effect of a medication or a treatment regimen to a subject suffering from a cancer, the method comprises: (A) obtaining a tissue from the subject; (B) dissociating the tissue to obtain a multicellular cluster, wherein the multicellular cluster comprises the cancer cell; (C) culturing the multicellular cluster on a cellulose sponge; (D) exposing the cultured multicellular cluster to the medication or the treatment regimen; and (E) measuring a first survival rate of the cancer cell before exposing to the medication or the treatment regimen and a second survival rate of the cancer cell after exposing to the medication or the treatment regimen, when the second survival rate is lower than the first survival rate, the method predicts positive effect of the medication or the treatment regimen to the subject.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: February 23, 2021
    Assignee: SHANXI PISHON BIOMEDICAL TECHNOLOGY CO., LTD
    Inventors: Chih-Chiang Hsieh, Yen Chang
  • Patent number: 10920215
    Abstract: The present invention provides a method of modifying a targeted site of a double stranded DNA, including a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded DNA and DNA glycosylase with sufficiently low reactivity with a DNA having an unrelaxed double helix structure (unrelaxed DNA) are bonded, with the double stranded DNA, to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into the targeted site, without cleaving at least one strand of the double stranded DNA in the targeted site.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: February 16, 2021
    Assignee: National University Corporation Kobe University
    Inventors: Keiji Nishida, Akihiko Kondo
  • Patent number: 10829787
    Abstract: Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells. The compositions and methods provided herein are particularly useful for the delivery of ribonucleoprotein complexes into pluripotent cells and lymphatic cells.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 10, 2020
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Xin Yu, Xiquan Liang, Xavier de Mollerat du Jeu, Robert Jason Potter
  • Patent number: 10799568
    Abstract: The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g. cancer, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: October 13, 2020
    Assignee: VALO THERAPEUTICS OY
    Inventors: Vincenzo Cerullo, Markus Vähä-Koskela, Mari Hirvinen, Cristian Capasso
  • Patent number: 10793924
    Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: October 6, 2020
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
  • Patent number: 10744198
    Abstract: Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites).
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 18, 2020
    Assignee: Najit Technologies, Inc.
    Inventors: Ian J. Amanna, Elizabeth A. Poore
  • Patent number: 10745715
    Abstract: The present invention relates to a producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises: i) a binding domain which binds to a capture moiety ii) a spacer; and iii) a membrane targeting domain such that, when incorporated a retroviral vector, the tagging protein facilitates purification of the retroviral vector from cellular supernatant via binding of the tagging protein to the capture moiety. The present invention also relates to a retroviral vector comprising such a producer cell-derived tagging protein.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 18, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Leila Mekkaoui, Gordon Weng-Kit Cheung
  • Patent number: 10696960
    Abstract: A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: June 30, 2020
    Assignee: TiumBio Co., Ltd.
    Inventors: In-Young Song, Hun-Taek Kim, Bong-Yong Lee, Mahn-Hoon Park, Ho-Soon Lee, Yun Jung Lim, Ji-Hye Lee, Seo Yeon Son, Min-Sun Kim
  • Patent number: 10676721
    Abstract: The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: June 9, 2020
    Assignees: Trustees of Boston University, Massachusetts Institute of Technology
    Inventors: James J. Collins, Michael Koeris, Timothy Kuan-Ta Lu, Gregory Stephanopoulos, Christopher Jongsoo Yoon
  • Patent number: 10660943
    Abstract: Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: May 26, 2020
    Assignee: The Rockefeller University
    Inventors: David Bikard, Luciano Marraffini
  • Patent number: 10639364
    Abstract: The present invention belongs to the field of animal health and provides means to study Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and for the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS. In a first consideration, the invention relates to a new PRRS virus variant. and, in a second consideration, to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone. Based on this, new PRRS vaccine candidates with improved properties are provided.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 5, 2020
    Inventors: Andreas Gallei, Christoph Keller, Erik Schacht, Marieke Herrel
  • Patent number: 10626394
    Abstract: Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Sebastien Lemire, Andrew C. Yang, Kevin M. Yehl
  • Patent number: 10618947
    Abstract: The present invention relates to a novel Hepatitis B virus (HBV) and/or Hepatitis D virus (HDV) receptor and its use for the development of cells, cell lines and non-human animals that are susceptible to HBV and/or HDV infection and can be used for immunological studies and/or for the screening of drugs, post-entry restriction factors and host dependency factors. It further relates to the use of the receptor for the identification of compounds useful in the treatment of HBV and/or HDV infection.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: April 14, 2020
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Stephan Urban, Yi Ni
  • Patent number: 10610552
    Abstract: A nutrient-germinant composition to aid in spore germination and a method for increased spore germination efficiency. The composition comprises L-amino acids, D-glucose and/or D-fructose, a phosphate buffer, an industrial preservative, and may include bacteria spores or they may be separately combined for germination. The method comprises providing a nutrient-germinant composition and bacteria spores, preferably of one or more Bacillus species, and heating to a preferred elevated temperature range of 41° C. to 44° C. for an incubation period of around 2 to 60 minutes. The nutrient-germinant composition is preferably in a concentrated liquid form that is diluted just prior to initiating the germination/incubation method at the point of use. The method may also include dispensing a germinated spore solution to a point-of-use/consumption, such as animal feed, water, or bedding, or a wastewater system or drain.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: April 7, 2020
    Assignee: NCH Corporation
    Inventors: Gabriel F. K. Everett, Charles Greenwald, Judy Pruitt, Amanda Rosmarin, Jordan Church, Daniel Aberle, George Aboagye
  • Patent number: 10588957
    Abstract: The present invention relates to a method for producing stabilised vaccines, the method comprising: (a) mixing antigens with a solution comprising: (i) chitosan; (ii) at least three different amino acids and/or at least one dipeptide or tripeptide; and (iii) a sugar; and (b) drying the mixture obtained in (a).
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: March 17, 2020
    Assignee: LEUKOCARE AG
    Inventors: Martin Scholz, Jens Altrichter, Kristina Kemter, Regina Scherliess, Hartwig Steckel
  • Patent number: 10577590
    Abstract: The present invention relates to a novel bacteriophage ?CJ28 (KCCM11466P) and a composition containing the same as an active ingredient. Further, the present invention relates to a method for preventing and/or treating infective diseases caused by enterotoxic Escherichia coli (ETEC) of animals excluding humans by using the composition.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: March 3, 2020
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Eun Mi Shin, Gi Duk Bae, Jae Won Kim
  • Patent number: 10577591
    Abstract: This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 3, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Mark J. Federspiel, Arun Ammayappan, Gennett Pike, Stephen James Russell
  • Patent number: 10550384
    Abstract: The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: February 4, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Srivatsan Raman, Noah D. Taylor, Jameson Rogers
  • Patent number: 10544399
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: January 28, 2020
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • Patent number: 10526393
    Abstract: The present invention relates to a method for promoting virus infection and increasing virus production, by using a cell line having lost Bst2 gene functions and, more specifically, to a method for promoting target virus infection and increasing target virus production, in addition to promoting virus budding and inhibiting host cell apoptosis by removing the Bst2 gene from a cell line having the ability to produce a virus. According to the present invention, the method for promoting target virus infection and increasing target virus production, by using an animal cell line having lost Bst2 gene functions, can improve production yields of a target virus and an antigen protein, and thus can be useful for the preparation of vaccines for treating and preventing viral diseases.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: January 7, 2020
    Assignee: IMMUNOMAX CO., LTD.
    Inventors: Se-Ho Park, Eunbi Yi